At a glance
- AOD-9604 is a modified peptide based on the C-terminal 176–191 region of human growth hormone, with an added tyrosine. It was developed to explore lipid-related effects without reproducing the full growth-promoting activity of HGH.
- AOD-9604 was investigated in human obesity programmes but did not become an approved weight-management medicine. Early or preclinical lipid signals should not be presented as established human fat-loss effectiveness.
- Compare AOD-9604 with HGH and the unmodified 176–191 fragment to separate sequence and full-hormone effects.
- Measure lipolysis, lipid storage, and growth-hormone-receptor signalling independently.
What AOD-9604 is—and what the name does not establish
AOD-9604 is a modified peptide based on the C-terminal 176–191 region of human growth hormone, with an added tyrosine. It was developed to explore lipid-related effects without reproducing the full growth-promoting activity of HGH.
Preclinical work proposed that the C-terminal fragment could influence lipolysis and fat accumulation through pathways distinct from the full growth-hormone receptor programme. In plain language, it isolates one proposed metabolic region of HGH rather than acting as replacement HGH.
Questions to settle before interpreting a result
A useful AOD-9604 study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Compare AOD-9604 with HGH and the unmodified 176–191 fragment to separate sequence and full-hormone effects.
- Measure lipolysis, lipid storage, and growth-hormone-receptor signalling independently.
- Treat clinical-development history as evidence of testing—not proof that the intended efficacy was established.
How to read the AOD-9604 evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Development history
- Design
- The obesity programme did not produce an approved medicine
- Finding
- AOD-9604 advanced beyond basic laboratory work, but clinical development did not establish a regulatory-approved weight-loss treatment. That negative or inconclusive history is part of the evidence.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Molecule distinction
- Design
- A fragment is not low-dose HGH
- Finding
- AOD-9604 contains only the C-terminal region plus a modification. It should not inherit growth, IGF-1, recovery, or safety claims from full-length somatropin.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Evidence lesson
- Design
- A discontinued efficacy programme still tells us something
- Finding
- When a candidate reaches human testing without becoming an approved therapy, that development history is more informative than repeating only its favourable preclinical rationale.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
AOD-9604 was investigated in human obesity programmes but did not become an approved weight-management medicine. Early or preclinical lipid signals should not be presented as established human fat-loss effectiveness.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Effects of human growth hormone and its lipolytic fragment AOD9604 on lipid metabolism in obese miceEndocrinology · 2001
Primary mouse study of a defined AOD9604 construct. It supports a preclinical metabolic hypothesis, not an approved human weight-loss claim.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for AOD-9604
This compound is not currently stocked. Add it to your five-choice catalogue ballot.